AbbVie (ABBV) stock has gained 24.0% compared with an increase of 34.3% for the industry in the past year, as seen in the chart below.Image Source: Zacks Investment ResearchAbbVie lost patent protection for its blockbuster immunology drug Humira in the United States in January 2023. Before it lost patent exclusivity, Humira accounted for a significant percentage of AbbVie’s sales, around 37% in 2022. Amgen (AMGN) was the first company to launch its Humira biosimilar. Thereafter, several other biosimilar ver ...

文章核心观点 - 这篇文章介绍了一些高收益的股息贵族公司,这些公司连续25年或更长时间提高了股息,被认为是优质和稳定的公司[1] - 尽管这些公司的股价也会下跌,但它们通常能够更快地反弹回来[2] - 这些公司的股息收益率是标准普尔500指数的近3倍,是很好的投资选择[5] 公司和行业总结 房地产投资信托(REIT)公司Realty Income (O) - Realty Income是一家月度派息的REIT公司,连续29年提高派息,是股息贵族中最出色的之一[6][7][9] - 该公司主要投资于零售物业,主要租户包括美元店、药店和便利店等[7][8] - 该公司的股息收益率为5.9%,其调整后的经营活动现金流(AFFO)可以支撑其股息[9] 包装公司Amcor (AMCR) - Amcor是全球最大的食品和饮料包装公司,受到通胀和高利率的影响,股价在过去一年中基本持平[11][12] - 但该公司作为行业龙头,可以通过规模优势来降低成本,并通过提高价格或转向利润更高的细分市场来提高利润[13] - 尽管增长不会太快,但该公司的股息收益率为5.1%,为投资者提供了稳定的收益[14] 制药公司AbbVie (ABBV) - AbbVie是一家制药公司,通过从母公司Abbott Labs分拆继承了其股息支付历史,过去10年股息复合年增长率达14%[15][16] - 尽管其主要药物Humira面临专利到期的挑战,但该公司仍有其他多个十亿美元级别的药品,并通过收购其他公司来拓展产品线[16][17][18] - 该公司的股息收益率为3.7%,股息支付能力很强[15] 消费品公司Kimberly-Clark (KMB) - Kimberly-Clark是一家消费品领导者,拥有多个知名品牌,在通胀压力下也能保持业绩[19][20] - 虽然消费者在通胀时会选择更便宜的产品,但当通胀缓解时他们通常会回到熟悉的品牌[21] - 该公司的股息增长率过去10年只有3.8%,但股息支付率仍然很安全[23] 消费健康公司Kenvue (KVUE) - Kenvue是强生公司(Johnson & Johnson)分拆出来的全球最大的消费健康公司,拥有知名品牌如泰诺、创可贴等[24][25] - 作为前母公司强生的继承者,Kenvue有望继续保持稳定的股息支付[25] - 该公司的股息收益率为4.3%[25] 可口可乐公司(KO) - 可口可乐是一家饮料巨头,虽然碳酸饮料消费呈下降趋势,但公司已转型为多元化的饮料公司[26][27][28] - 公司拥有强大的分销网络,可以快速推广新产品[28] - 公司有57年的连续增加股息的历史,过去10年股息复合增长率为4.8%,最近一次增幅为5.4%[29] 石油公司雪佛龙(CVX) - 雪佛龙是全球第二大综合性石油天然气公司,在疫情期间没有暂停或减少股息[30][31] - 即使油价下跌至每桶50美元,公司也能保持盈利并支付股息[31] - 公司未来5年内现金流有望超过一倍,为股息支付提供保障[31] - 公司当前股息收益率为4.1%[31]

NORTH CHICAGO, Ill., July 2, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2024 financial results on Thursday, July 25, 2024, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solut ...

One of the most important sectors in any country’s economy is the biotech sector. Picking under-the-radar biotech stocks is easier said than done because we do not see immediate results. These companies have to move past the clinical trials and then prove that their drug or treatment is effective and safe.There are times when many of these candidates hit a dead wall, and the investment and research both go in vain. But if the company proves its worth, the rewards will be significant. This is why it takes a ...

Retirement stocks are something every investor needs to look into, and when deciding on which retirement stocks to buy, you can never go wrong with Dividend Kings, S&P 500 index constituents that have raised their dividends every one of the previous 25 straight years.Dividend growers had 11.7% compound annual returns from 1986 to 2016, while dividend payers had 9.9%. Dividend stocks are more resilient, so this outperformance is even greater during market volatility. This is great, since the markets are stil ...

文章核心观点 - AbbVie的药物Tepkinly(epcoritamab)获得欧洲药品管理局(EMA)的CHMP委员会的正面意见,建议批准其用于治疗复发/难治性滤泡性淋巴瘤(R/R FL)的扩展适应症[1][2][6] - 如果获批,Tepkinly将成为欧盟首个获批用于治疗R/R FL和R/R DLBCL的双特异性抗体单药疗法[4] - AbbVie与Genmab合作开发Epkinly/Tepkinly,双方在美国和日本分担商业责任,AbbVie负责全球商业化[7][8] - AbbVie在2024年第一季度从Epkinly和Tepkinly的收益中获得2700万美元[9] - AbbVie和Genmab正在评估Epkinly作为单药和联合用药在多种血液肿瘤适应症中的疗效[10] 行业相关 - 滤泡性淋巴瘤(FL)是最常见的一种慢性非霍奇金淋巴瘤,而弥漫大B细胞淋巴瘤(DLBCL)是最常见的一种急性非霍奇金淋巴瘤[5] - 默克公司的肺动脉高压药物Winrevair获得CHMP的正面意见,有望成为欧洲首个激活素信号抑制剂疗法[11] - 强生公司的Balversa获得CHMP的正面意见,用于治疗FGFR基因改变的晚期或转移性膀胱癌[12]

As Previously Announced, Richard A. Gonzalez Retires as Chief Executive Officer to Become Executive ChairmanRobert A. Michael Joins AbbVie Board of DirectorsNORTH CHICAGO, Ill., July 1, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that Robert A. Michael has assumed the role of chief executive officer (CEO) and has joined AbbVie's Board of Directors, effective today. As previously announced, Mr. Michael succeeds Richard A. Gonzalez, who has served as CEO since the company's inception in 2013. Mr. ...

These stocks could be ideal for investors in their golden years.Most retirees prefer low turnover in their investment portfolios. The less drama, the better. That way, they can focus on doing what they enjoy instead of worrying about their investments.Three Motley Fool contributors think they've found magnificent stocks retirees can buy and hold forever. Here's why they picked AbbVie (ABBV 1.50%), Gilead Sciences (GILD -0.32%), and Johnson & Johnson (JNJ 0.25%).A Dividend King poised for growthKeith Speight ...

AbbVie (ABBV) announced that it has acquired Celsius Therapeutics, a private biotech making novel therapies for treating inflammatory bowel diseases (“IBD”).The acquisition will add Celsius Therapeutics’ lead pipeline candidate, CEL383, to AbbVie’s pipeline. CEL383 is a potential first-in-class TREM1 inhibitor, which has completed phase I study in IBD conditions. AbbVie will pursue further development of CEL383.TREM1 has been identified as a key gene involved in inflammation pathways associated with IBD. In ...

If approved, epcoritamab (TEPKINLY®) will become the first and only bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of prior therapyPositive CHMP opinion based on results from the Phase 1/2 EPCORE® NHL-1 studyNORTH CHICAGO, Ill., June 28, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) ...